Characteristics and costs of carbapenemase-producing enterobacteria carriers (2012/2013)

Medecine et Maladies Infectieuses

Volumn 44, Issue 7, 2014, Pages 321-326

  Daroukh, A ^a   Delaunay, C ^a   Bigot, S ^a   Ceci, J M ^a   Siddhoun, N ^a   Bukreyeva, I ^a   Raisin, J ^a   Porcheret, H ^a   Maisonneuve, L ^a   Bouldouyre, M A ^a  

^a Centre Hospitalier Robert Ballanger CHRB   (France)

Author keywords

Carbapenemase; Carbapenemase cost; Carbapenemase isolation

Indexed keywords

AGED; ARTICLE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTACT EXAMINATION; DISEASE CARRIER; FEMALE; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; MALE; MANAGED CARE; MORTALITY; PATIENT CARE; PATIENT IDENTIFICATION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; ANTIBIOTIC RESISTANCE; CROSS INFECTION; ECONOMICS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; EPIDEMIC; FRANCE; GENERAL HOSPITAL; GENETICS; HETEROZYGOTE; HOSPITAL COST; HOSPITAL PERSONNEL; HOSPITAL SUBDIVISIONS AND COMPONENTS; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIOLOGY; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE;

AGED; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; CARRIER STATE; CROSS INFECTION; DISEASE OUTBREAKS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FRANCE; HOSPITAL COSTS; HOSPITAL UNITS; HOSPITALS, GENERAL; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT ISOLATION; PERSONNEL, HOSPITAL; RETROSPECTIVE STUDIES;

EID: 84905029517     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2014.06.004     Document Type: Article

References (18)

1. Abbas M., Cherkaoui A., Fankhauser C., Harbarth S., Schrenzel J. Carbapénémases: implications cliniques et épidémiologiques pour la Suisse. Rev Med Suisse 2012, 8:882-889.
2. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 2014, 44(2):51-56.
3. Gupta N., Limbago B.M., Patel J.B., Kallen A.J. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011, 53(1):60-67.
4. Won S.Y., Munoz-Price L.S., Lolans K., Hota B., Weinstein R.A., Hayden M.K. Emergence and rapid regional spread of Klebsiella pneumoniae carbapemenase-producing Enterobacteriaceae. Clin Infect Dis 2011, 53(6):532-540.
5. Palmore T.N., Henderson D.K. Managing transmission of carbapenem-resistant enterobacteriaceae in healthcare settings: a view from the trenches. Clin Infect Dis 2013, 57(11):1593-1599.
6. Haut conseil de santé publique Recommandations pour la prévention de la transmission croisée des «bactéries hautement résistantes aux antibiotiques émergentes (BHRe)». Rapport du Haut conseil de santé publique 2013, http://www.hcsp.fr/Explore.cgi/Telecharger%3FNomFichier=hcspr20130710_recoprevtransxbhre.pdf.
7. Lloyd-Smith P., Younger J., Lloyd-Smith E., Green H., Leung V., Romney M.G. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay. J Hosp Infect 2013, 85(1):54-59.
8. Giske C.G., Monnet D.L., Cars O., Carmeli Y. Clinical and economic impact of common multi-drug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008, 52(3):813-821.
9. Lautenbach E., Patel J.B., Bilker W.B., Edelstein P.H., Fishman N.O. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001, 32:1162-1171.
10. Lee S.Y., Kotapati S., Kuti J.L., Nightingale C.H., Nicolau D.P. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Edidemiol 2006, 27(11):1226-1232.
11. Schwaber M.J., Navon-Venezia S., Kaye K.S., Ben-Ami R., Scwartz D., Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006, 50(4):1257-1262.
12. Cosgrove S.E., Kaye K.S., Eliopoulos G.M., Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002, 162:185-190.
13. Lemos E.V., De la Hoz F.P., Alvis N., Einarson T.R., Quevedo T.R., Castaneda C., et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumanii infection in Colombia. Clin Microbiol Infect 2014, 20(2):174-180.
14. Mauldin P.D., Salgado C.D., Hansen I.S., Durup D.T., Bosso J.A. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 2010, 54(1):109-115.
15. Roberts R.R., Hota B., Ahmad I., Scott R.D., Foster S.D., Abbasi F., et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009, 49(8):1175-1184. http://www.ncbi.nlm.nih.gov/pubmed/19739972%20-
16. Tansarli G.S., Karageorgopoulos D.E., Kapaskelis A., Falagas M.E. Impact of microbial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther 2013, 11(3):321-331.
17. Ng E., Earnest A., Lye D.C., Ling M.L., Ding Y., Hsu L.Y. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals. Ann Acad Med Singapore 2012, 41:189-193.
18. Lye D.C., Earnest A., Ling M.L., Lee T.E., Yong H.C., Fisher D.A., et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteriema on mortality and length of stay: cohort study. Clin Microbiol Infect 2012, 18:502-508.